Printer Friendly

OliX Pharmaceuticals signs license and collaboration agreement with Thea Open Innovation.

M2 EQUITYBITES-March 18, 2019-OliX Pharmaceuticals signs license and collaboration agreement with Thea Open Innovation

(C)2019 M2 COMMUNICATIONS http://www.m2.com

OliX Pharmaceuticals Inc (Kosdaq: 226950), a developer of RNAi therapeutics, has signed a license and collaboration agreement with Thea Open Innovation, part of the Laboratoires Thea SAS, a French independent pharmaceutical company, it is reported today.

The collaboration is aimed at developing and commercialising the OLX301A program, a novel treatment for dry and wet age-related macular degeneration.

Under the contract, OliX receives a non-refundable and non-creditable upfront payment of EUR2m and is eligible to receive milestone payments upon achievement of clinical milestones and royalty for the development and commercialisation.

Thea has been granted licensing rights for OLX301A program in EU countries, Middle East and Africa. OliX continues to hold the rights of OLX301A program for the US and Asia.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Mar 18, 2019
Words:152
Previous Article:Hardy Diagnostics forms strategic urogenital testing distribution partnership with EliTech.
Next Article:Mercedes-Benz UK opens order book for Mercedes-AMG GT R PRO.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |